Immatics Biotechnologies GMBH’s latest financing starkly illustrates the difference between biotech exit opportunities in the U.S. and in Europe, where companies are returning to their venture backers to fund even promising late-stage cancer immunotherapy programs that would surely attract IPO buzz in the U.S.
Germany's immatics has raised €34 million ($46 million) from existing investors to complete Phase III clinical development of its lead...
Welcome to Pink Sheet
Create an account to read this article
Already a subscriber?